Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
RESEARCH TOOLSreports
SANA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.52 - $12.00
Previous CloseN/A
Volume118.31M
Average Volume (3M)12.15M
Market Cap
$674.27M
Enterprise Value$872.56M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Mar 13, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding223,268,890
10 Day Avg. Volume2,788,944
30 Day Avg. Volume12,147,714
Standard Deviation0.29
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-28.27
Enterprise Value/Ebitda-3.03
Forecast
1Y Price Target
$11.25Price Target Upside267.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Sana Biotechnology News
PremiumCompany Announcements
Sana Biotechnology Shows Promise with Hypoimmune Platform
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNo adverse events or serious adverse events were observed, and the patient achieved detectable C-peptide levels and HIP islet cell survival up to 28 days post-treatment.
EarningsSANA shares are soaring +300% after market close after announcing results from the FIH IST of UP421 in a patient with T1D which demonstrated islet cell engraftment, avoidance of immune response and production of insulin.
Product DevelopmentThe world's first HIP islet cell transplant was successfully performed without any immunosuppression, demonstrating the potential of Sana's technology.
Bears Say
Development ChallengesSC451 remains at an early stage of development and open questions remain on durability and manufacturing.
Market PotentialIt is still very early to determine if the product will be able to replicate this success in a larger patient population and at full doses.
Safety And EfficacyThe lack of any safety signal is encouraging for higher dosing, though additional patients may be needed to confirm the safety profile across both volatile and controlled diabetics.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.52 and its highest was $12.00 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $674.27M.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Mar 13, 2025 which is in 19 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Nov 08, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.257 by $0.007.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.25.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 223,268,890 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.257. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
---
Sana Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (267.65% Upside)
$11.25 (267.65% Upside)
Blogger Sentiment
Neutral
SANA Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.40%
12-Months-Change
Fundamentals
Return on Equity
-92.90%
Trailing 12-Months
Asset Growth
-11.41%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases.
---
SANA Stock 12 Month Forecast
Average Price Target
$11.25
▲(267.65% Upside)
Technical Analysis
Arcturus Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering SANA
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-14.86%
reiterated a buy rating 2 months ago
Copying Samantha Semenkow's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -14.86% per trade.
---